Company Directory - Novartis AG
Company Details - Novartis AG

Novartis AG
WebsiteBasel, Switzerland
NYSE: NVS, Swiss Exchange: NOVN
ISIN: CH0012005267
140 Locations
Novartis AG is a global healthcare company that provides innovative healthcare solutions to meet the evolving needs of patients worldwide, focusing on both patented medicines and generic pharmaceuticals.
CCI Score
CCI Score: Novartis AG
2.88
-0.01%
Latest Event
Novartis 2024 Political Contributions and Lobbying Activity
Novartis AG's profile reveals that during the 2024 cycle, the company contributed approximately $972,834 in campaign donations and spent around $6,220,000 on lobbying activities, including allocations to dark money groups and super PACs. This data, released by the FEC and Senate records in early 2025, highlights the company's significant political influence efforts.
Take Action
So what can you do? Support Novartis by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
OBJECTOR
Novartis AG is currently rated as an Objector.
Latest Events
- FEB062025
Novartis AG's profile reveals that during the 2024 cycle, the company contributed approximately $972,834 in campaign donations and spent around $6,220,000 on lobbying activities, including allocations to dark money groups and super PACs. This data, released by the FEC and Senate records in early 2025, highlights the company's significant political influence efforts.
-50
Political Contributions and Lobbying Efforts
April 30
The disclosed political contributions and substantial lobbying expenditures, particularly involving dark money channels, raise concerns about the potential alignment with entrenched, non-transparent political interests. Such practices may contribute to undue influence over policy-making and indirectly support authoritarian tendencies, warranting a negative assessment through an anti-fascist lens.
- JAN012025
The FEC record for the Novartis Corporation Political Action Committee details relatively low political contributions and disbursements, with total receipts of $64,076.17 and total disbursements of $68,784.57. This data indicates minimal involvement in political funding, suggesting a neutral position in terms of partisan influence or support for authoritarian policies.
+0
Political Contributions and Lobbying Efforts
April 30
The committee's financial summary reflects very modest contributions and expenditures, which implies that Novartis is not actively engaging in political funding that would support far‐right or authoritarian agendas. This neutral level of activity is notable given the current political climate.
- APR092024
Novartis announced plans on April 9, 2024 to lay off 680 staff members across its development organization in Switzerland and the United States over the next two to three years. The move is part of a restructuring effort that follows previous layoffs, causing concerns over worker job security and labor rights.
-50
Labor Relations and Human Rights Practices
April 30
The planned layoffs of 680 employees reflects a negative impact on labor relations and human rights practices. This decision undermines job security and worker protections, which is particularly concerning from an anti-fascist perspective that values strong labor rights and the protection of marginalized workers.
- JAN012024
Novartis has updated its approach to managing labor rights risks in its supply chain by implementing an enhanced External Partner Risk Management framework, launching its Labor Rights 2.0 program in 2024, and introducing a digital workers voice platform. These initiatives aim to safeguard vulnerable workers and ensure compliance with human rights standards among external partners.
+80
Labor Relations and Human Rights Practices
April 30
Novartis’s launch of Labor Rights 2.0 and its digital 'workers voice' platform represents a strong commitment to protecting labor rights. The efforts to conduct risk assessments, audits, and corrective actions, especially regarding allegations of forced labor, improve protections for vulnerable workers in the supply chain, marking a positive step against exploitative practices.
+75
Supply Chain Ethics
April 30
The detailed External Partner Risk Management (EPRM) framework and targeted assessments for high-risk external suppliers in the supply chain indicate a proactive approach to addressing human rights risks, including risks of forced labor in raw material sourcing.
- DEC312023
Novartis AG spent $5,930,000 on federal lobbying activities during 2023, as reported by OpenSecrets using Senate Office of Public Records data. The expenditure reflects the company's effort to influence public policy and regulatory decisions.
-40
Political Contributions and Lobbying Efforts
April 30
The reported nearly $6M lobbying expenditure indicates a significant investment in political influence. From an anti-fascist perspective, such heavy spending on lobbying may help entrench corporate interests over democratic accountability and can potentially support policies favoring authoritarian or undemocratic approaches.
- DEC312023
Novartis released its detailed report on child labor due diligence for the period January 1, 2023, to December 31, 2023, demonstrating compliance with Swiss regulations and a robust system for monitoring, auditing, and remediating child labor risks within its supply chain.
+70
Labor Relations and Human Rights Practices
April 30
Novartis has implemented comprehensive due diligence procedures to ensure compliance with international labor standards regarding child labor. The report details rigorous audits, clear remediation measures, and strict enforcement of ethical policies, reflecting a strong commitment to protecting human rights in its operations and supply chain.
PDF Novartis report on child labor due diligence in our supply chain
+65
Supply Chain Ethics
April 30
The report highlights a rigorous approach to supply chain risk management by screening thousands of third parties and enforcing corrective actions via audits and remediation plans. These practices underscore Novartis's commitment to ethical supply chain management and reducing human rights risks, including those related to child labor.
PDF Novartis report on child labor due diligence in our supply chain
- NOV012023
Novartis has detailed its lobbying expenditures in compliance with US federal law and EU regulations, emphasizing a commitment to transparency and responsible engagement in public policy. The company outlines its approach to evidence-based dialogue with policymakers, aiming to support innovation and positive impacts on healthcare policy.
+40
Political Contributions and Lobbying Efforts
April 30
Novartis demonstrates responsible political behavior by transparently disclosing all lobbying expenditures and engaging in evidence-based policy dialogue. This adherence to legal requirements and ethical standards contributes positively to democratic processes and accountability, countering tendencies toward opaque corporate political influence.
- NOV012023
Novartis outlined its public policy approach, emphasizing transparent and ethical lobbying practices. The company details adherence to federal contribution limits for its PAC, a commitment to evidence‐based dialogue with policymakers, and a focus on creating progressive legislative foundations to support innovation in healthcare.
+40
Political Contributions and Lobbying Efforts
April 30
The article notes that Novartis follows strict federal contribution limits and clear guidelines in managing its PAC. This transparent approach to political contributions and ethical lobbying practices promotes accountability in public affairs, aligning with democratic, anti-authoritarian principles.
+50
Executive Political Engagement
April 30
Novartis demonstrates responsible executive political engagement by actively participating in policy discussions, emphasizing evidence-based data and transparent practices. Its commitment to constructive dialogue with regulatory bodies and governments positively contributes to a progressive legislative environment.
- JUL012020
Novartis Pharmaceuticals Corporation agreed to pay over $642 million to settle allegations of fraudulent use of copay assistance foundations and kickbacks to doctors, practices that involved manipulating Medicare patient copay processes and scheduling speaker programs as a means to drive prescriptions.
-80
Business Practices and Ethical Responsibility
April 30
The settlement details reveal that Novartis engaged in unethical business practices by channeling payments through foundations to cover patient copays and by providing kickbacks to physicians. These actions not only manipulated Medicare mechanisms and contributed to increased healthcare costs, but also undermined public trust in the healthcare system. Such behavior is indicative of a broader disregard for ethical business practices, warranting a strongly negative score in the Business Practices and Ethical Responsibility category.
- JUN012017
Novartis released an updated Corporate Responsibility Guideline outlining its internal governance framework and commitment to ethical business practices including transparent oversight, access to medicine initiatives, and integration of corporate responsibility metrics into executive performance. The document, approved in its latest update in June 2017, details the roles of the Corporate Responsibility Board, Governance Committees, and cross-divisional coordination aimed at improving global health and ensuring responsible operations.
+50
Business Practices and Ethical Responsibility
April 30
The guideline demonstrates Novartis' positive commitment to ethical business practices by instituting robust corporate responsibility governance, transparency in reporting, and clear accountability measures. These actions support progressive values and help mitigate risks associated with corporate complicity in authoritarian or exploitative practices.
- OCT292011
Unions in Basel protested Novartis' announcement of cutting 2,000 jobs, arguing that the company's decision to prioritize profits over job security undermines worker rights. The cuts include 1,100 domestic positions and 900 in the United States, while 700 new roles are planned in low-cost countries.
-60
Labor Relations and Human Rights Practices
April 30
Novartis' decision to cut a significant number of jobs, impacting domestic employment and sparking union protests, reflects a disregard for worker welfare. This move prioritizes profit over the rights and security of workers, aligning with practices that undermine labor relations and human rights.
Alternatives

Basel, Switzerland
-19.51

Kenilworth, United States
2.79

Indianapolis, United States
-34.93
Corporation
2.29

Corporation
-11.98

Japan
25.97

Corporation
0.48

Belgium (Ghent), Belgium
78.10

Barcelona, Spain
56.89
Raleigh, USA
55.85
Corporate Financials
- Revenue
- 2025
- $51.20B
- Total Assets
- 2025
- $113.50B
- Operating Income
- 2025
- $12.03B
- Total Equity
- 2025
- $67.80B
Employees: 109,000
Industries
- 325411
- Medicinal and Botanical Manufacturing
- 325412
- Pharmaceutical Preparation Manufacturing
- 541711
- Research and Development in Biotechnology